Craig Titmus
UK & European Patent Attorney

Craig holds a bachelor’s degree in molecular biology and biochemistry, as well as a PhD in biotechnology. He entered the profession in 2009, qualified as a European Patent Attorney in 2013 and then as a Chartered Patent Attorney in 2014. Craig works on a wide variety of technical subjects, specialising in the fields of biotechnology, biochemistry and life sciences. In Legal 500 it is noted that Craig is an 'excellent' patent attorney, with 'strong technical backgrounds and highly developed legal skills’ (2017). 


Year joined: 2014

Qualifications: BSc PhD (Cantab) EPA CPA


Craig’s main practice areas include drafting, prosecuting and managing global patent families. He also works on European opposition and appeal cases, as well as competitor surveillance. Craig has particular expertise in vaccines, diagnostics, recombinant protein and nucleic acid technologies, as well as plant molecular biology, plant protection products and biofuels.


Craig gained a first class bachelor’s degree in molecular biology and biochemistry at the University of Durham where he ranked top in his year. He went on to the University of Cambridge to undertake a PhD in collaboration with a multinational crop research company, focussing on environmental stress tolerance in plants and the interfaces between metabolism and the cell cycle. During his time at Cambridge, Craig was awarded various PhD prizes within the Institute of Biotechnology. He also holds a certificate in Intellectual Property from the University of London as well as an Intellectual Property Litigation Certificate.

Membership & Organisations

Craig is a member of CIPA and EPI.

Recent Work

Craig has presented on the challenges of stem cell patentability in Europe and provided practical advice on how to obtain commercially-relevant patents in this technical field.  A link to the full presentation is provided below.

European and US Patent Strategies for Cell Therapies


  • Patent applications

  • patent drafting and filing
  • freedom to operate
  • due diligence
  • patent enforcement
  • IP strategy
  • patent portfolio management
  • licensing
  • patent oppositions
  • commercialisation 

Follow us on twitter